Bio-Rad Laboratories, Inc. (BIO) Earnings Call Analysis

NYSE · Healthcare · Medical Devices

13/25

Growth 1 Margin 3 Expansion 4 Platform 1 Financial 4

latest quarter score

Earnings Reports

13
Bio-Rad (BIO) Q2 2026: Digital PCR Instrument Sales Surge 20%, Restructuring Targets $35M Cost Savings
August 05, 2026
11
Bio-Rad (BIO) Q1 2026: Middle East Disruption Cuts $11M From Diagnostics, Margin Guidance Tightens
June 17, 2026
14
Bio-Rad (BIO) Q3 2025: Process Chromatography Delivers Double-Digit Growth, Offsetting U.S. Research Weakness
June 16, 2026
15
Bio-Rad (BIO) Q4 2025: Process Chromatography Set for Mid-Teens Decline, Reshaping Segment Mix
June 15, 2026
13
Bio-Rad (BIO) Q4 2025: Process Chromatography Slumps Mid-Teens, Margin Recovery Hinges on Operational Execution
June 15, 2026
17
Bio-Rad (BIO) Q2 2025: Process Chromatography Jumps 25%, Offsetting Academic Market Drag
July 31, 2025
17
BioRad (BIO) Q1 2025: Tariffs Cut 130bps From Margin as Life Science Softness Deepens
July 04, 2025
Bio-Rad (BIO) Q3 2024: Clinical Diagnostics Up 6%, Process Chrome Destocking Persists Into 2025
October 30, 2024
Bio-Rad (BIO) Q2 2024: Process Chromatography Declines 16%, Margin Expansion Offsets Life Science Drag
August 01, 2024
Bio-Rad (BIO) Q1 2024: Non-GAAP Operating Margin Drops to 9.7% as Process Chromatography Softens
May 07, 2024
Bio-Rad (BIO) Q4 2023: Life Science Revenue Down 19%, Diagnostics Steady as Recovery Hinges on H2
February 15, 2024
BioRad (BIO) Q3 2023: Life Science Revenue Down 17%, China and Biopharma Weakness Drive Guidance Reset
October 26, 2023
16
Bio-Rad (BIO) Q2 2023: Process Chromatography Down Mid-Teens, Diagnostics Outpaces Life Science Recovery
August 03, 2023
Bio-Rad (BIO) Q1 2023: Core Sales Up 6%, Margin Compression Signals Operational Reset
May 04, 2023
Bio-Rad (BIO) Q4 2022: Life Science Core Revenue Jumps 28% as Digital PCR and Chromatography Drive Growth
February 15, 2023

Browse all companies